AI-powered health and life sciences firm ConcertAI has unveiled its new predictive and GenAI solutions, expansions in partnerships, and a clinical oncology suite designed to enhance research capabilities and support complex clinical study workflows. These solutions aim to provide researchers with enhanced in-depth data analysis facilities, contributing to the creation of new care strategies to improve patient outcomes.

The company’s new GenAI solutions include 1) CARA AI, a comprehensive multi-modal data management platform designed to advance research across multiple fields, support collaborations, and manage multi-modal real-world data, and 2) TriaLinQ, a clinical trial screening system (as part of ConcertAI’s oncology quality management platform SmartLinQ) capable of screening 3x more patients than electronic medical records (EMR)-based screening.

The Massachusetts-based company offers an oncology-focused Saas platform that incorporates real-world data (RWD) to support drug developers and pharmaceutical companies in expediting drug discovery and development. It reportedly maintains the largest oncology database in the industry, with data gathered from various sources, including the FDA. It also offers clinical trial technology support platforms that assist with clinical trial management specializing in solutions for oncology-related trials.